Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer
Medroxyprogesterone acetate (MAP) in the treatment of advanced breast cancer has been regarded as a minor agent according to the previous reports when used at low doses (<500 mg/day). High doses of more than 500 mg which have come into use since 1973 give a response rate of over 40%, but sometimes cause gluteal abcess or induration because of daily intramuscular injections.
In order to administer easily and to avoid the side effect, we have attempted to use oral administration in a daily dose of 1200mg (400 mg × 3). Of those 20 patients treated with oral high-dose MAP, 1 showed complete response, 6 showed partial response, 7 no change, and 6 progressive disease. As for site of lesion, 4 out of 6 (67%) in skin and 4 out of 16 (25%) in bone responded. Neither severe side effects nor abnormal laboratory data were seen.
Then, we examined the blood levels of MAP in vivo by RIA in 9 patients. The blood level of MAP reached 39–250 ng/ml in 3 days and was maintained at least over 50 ng/ml for 1 or 2 months of continuous administration. Subsequently, we examined the effects of MAP on binding to ER in vitro. The inhibition of binding of estradiol-17β to ER was about 60% at 10−5 M MAP. The blood level of 50 ng/ml in vivo corresponds to about 1.3 × 10−5 M.
Keywordsmedroxyprogesterone acetate (MAP) oral high-dose hormone therapy breast cancer
Unable to display preview. Download preview PDF.
- 1.Ganzina F: High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori 65: 563–585, 1979.Google Scholar
- 2.Pannuti F, Martoni A, Pollutri E, Camera P, Lenaz GR: Medroxyprogesterone acetate (MPA): Effect of massive doses in advanced breast cancer. IRCS Med Sci 2: 1065, 1974Google Scholar
- 3.Amadori D, Ravaioli A, Barbanti F: L'impiego del Medrossiprogesterone acetato ad alti dosaggi nella terapia palliativa del carcinoma mammario in fase avanzata. Min Med 67: 1–14, 1976Google Scholar
- 7.Mattsson W: High dose medroxyprogesterone acetate treatment in advanced mammary carcinoma. A phase II investigation. Acta Radiol Oncol 17: 387–400, 1978Google Scholar
- 9.Iino Y, Izuo M, Takikawa H: A study of estrogen and progesterone receptors in human breast cancer by sucrose gradient centrifugation. Jpn J Clin Oncol 10: 49–60, 1980Google Scholar
- 10.Pannuti F, Di Marco AR, Martoni A, Fruet F, Strocchi E, Burroni P, Rossi AP, Cricca A: Medroxyprogesterone acetate in treatment of metastatic breast cancer: Seven years of experience,In S Iacobelli and A Di Marco (eds): Role of Medroxyprogesterone in Endocrine-related Tumors. Raven Press, New York, 1980, pp 73–92Google Scholar
- 16.Tanaka M, Abe K, Ohnami S, Adachi I, Yamaguchi K, Minakawa S: Tamoxifen in advanced breast cancer: Response rate, effect on pituitary hormone reserve and binding affinity to estrogen receptor. Jpn J Clin Oncol 8: 141–148, 1978Google Scholar